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Oxprenolol (Trasicor), a beta-receptor blocking agent
widely used in angina pectoris, was evaluated for its
possible arrhythmogenic or antidys.rhythmic effects. In a
,randomised double-blind within-patient trial, 44 physically
active postmyocardial infarction patients completed the
trial. Ventricular ectopic activity was evaluated on a
magnetic tape and recorded over 7-hour periods while
the patients were active at work. No deleterious effects
were noted in 73%, an increase in electrical stability
was noted in 23% and only one patient was evaluated as
being worse while on the drug.
S. Air. Med. J., 48, 1073 (1974).
The widespread use of beta-receptor blocking agents in
ischaemic heart disease is presently well established. As it
is currently believed that the high incidence of sudden
death in the~e high-risk patients is related to electrical
instability of the myocardium: the negative chronotropic
effect of these agents might theoretically lead to ventri-
cular escape rhythms with deleterious results. This study
reports the effect of oxprenolol on ventricular ectopic
activity in active postmyocardial infarction patients. From
the beta-receptor blocking agents currently available,
oxprenolol was selected because of its beta-stimulating
and its local anaesthetic properties on the myocardium.'
PATIENTS AND METHODS
Fifty patients who had suffered an acute myocardial
infarction (AMI) more than one month previously and
on normal daily activity, were studied. They were divided
into two groups according to the time elapsed since
infarction. Group I included 36 patients studied less
than 3 months after infarction, and group II included 14
patients 3 months or longer after infarction.
Detailed documentation in regard to hospital course
and functional status at the time of evaluation was
available in all cases. No patient was suffering from
angina pectoris and no-one was on anti-arrhythmic drugs
at the onset of the trial. The purpose of the study was
1 Military Hospital and Military Medical Institute, Voor-
trekkerhoogte, Tv)
D. P. MYBURGH, SM, M.B. CH.B.
-----------
Date received: 14 January 1974.
Reprint reque,1S to: CoL D. P. Myburgh, Milirary Medical Institute,
p.a. Tek, Verwoerdburg, TvL
explained and the patients' co-operation ascertained. They
were required to keep a diary and to log assessments on
visual analogue scales. Special emphasis was placed on
general feeling oCwell-being, chest pain and the awareness
of palpitations.
The trial was designed as a randomised double-blind
within-patient study. Oxprenolol in a fixed dose of 40 mg
(.d.s. for 2 weeks and then placebo, or vice versa, was
evaluated. On day 1, a history, physical examination,
resting ECG, chest X-ray films, fasting blood sugar, serum
lipids, uric acid and thyroxin, and a control 7-hour ECG
on magnetic tape" were obtained. On day 2, therapy was
initiated and the above-mentioned investigations repeated
on day 14. On day 15 the alternative therapeutic regimen
started and a similar evaluation was performed on day
28. The magnetic tapes were recorded with the patients
active at work, but they were instructed, to the best of
their ability, to see that their activities remained the same
on the days of monitoring. The quanta of ventricular
ectopic beats (YEB) were graded from 0 to 4 (Table I),
and a positive or negative result was documented only
when the quantum changed by one or more grades.
TABLE I. GRADING OF NUMBER OF VENTRICULAR ECTOPIC
BEATS
Approximate
Total No. of No. of VES
No. of VES VES over per normal
Grade per hour 7 hours sinus beat
0 0 0 0
1 <1 1 - 6 <1/3600
2 1 - 7 7 - 49 1/3600 - 1/500
3 8-50 50 - 350 1/500 - 1/70
4 >50 >350 >1/70
RESULTS
In group 1, 6 patients did not complete the trial-for
reasons which were not drug-related. The results, in
regard to the change in the absolute number of VEB
while on oxprenolol, are shown in Table IL It is evident
that in most cases no impressive change occurred. A
definite decrease in the quantum of VEB was observed
in 11 (25%) of the cases on oxprenolol. Only one patient
in the entire group was evaluated as being worse.
This patient had 17 VEB over the control 7-hour testing
period, >1 000 VEB while on oxprenolol and zero VEB
while on the placebo, and was thus graded as 2 - 4 - 0,
according to the classification.
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TABLE 11. NUMBER OF VEB WHILE ON OXPRENOLOL
Patients Unchang~d Decreased Increased Total
Group 1 22 (73%) 7 (23%) 1 (3%) 30
(1 - 3 months
after AMI)
Group 2 10(71%) 4 (29%) 14
(3 months
after AMI)
Total 32 (73%) 11 (25%) 1 (2%) 44
TABLE Ill. PATIENTS' SELF-ASSESSMENT WHILE ON
OXPRENOLOL
Patients Unchanged Better Worse Total
Group I 14 (47%) 12 (40%) 4 (13%) 30
Group 11 9 (64';10) 1 (7%) 4 (29%) 14
Total 23 (52%) 13 (30%) 8 (18%) 44
The patients' preference in regard to a feeling of well-
being whi~e on oxpreno:o! versus placebo is depicted in
Table Ill. The subjective assessment regarding palpitations
proved to be unrealistic. Even although they were specifi-
cally asked to assess the incidence of palpitations, most
patients were quite unaware of them. No statistically
significant change was ob,erved in the patient's functional
status, resting ECG, heart size on X-ray film, fasting blood
sugar, serum lipids, uric acid or thyroxin determination.
DISCUSSION
It has been shown that in patients with ischaemic heart
disease, the manifested VEB tend to remain remarkably
constant in individual patients. This behaviour is reflected
in both the total number of YEB over extended periods of
time as well as in the configuration of these YEB, thus
bringing about a valid model for the evaluation of a
drug's possible effects on the rhythm of the heart:
Tt is also evident that the wide variation in coupling
periods of YEB with identical configuration strengthens
the possibility that an automatic firing focus is operating
in many.; Thus any drug with negative chronotropic
qualities would theoretically potentiate manIfestation of
such a focus.
In the present study no significant difference in the
total number of YEB was noticed in 73% of patients, a
decrease in 25%, and an increase in only 2% while on
oxprenolol. Admittedly a slower heart rate was not aimed
at with the dose employed. On the other hand, the
relative influence of the supposedly detrimental negative
chronotropic effect versus the beneficial membrane
anaesthetic effect of the drug, is still unexplained. Also the
suggestion that bradycardia predisposes to malignant
ventricular dysrhythmia·" may not be totally correct,
and, in fact, a relative bradycardia per se may exert a
protective function ..·• In contrast with an automatic tiring
focus, if a re-entry mechanism is implicated in these
patients, again the change in rate, whether faster or slower,
must be very critical for the manifestation of ectopic
beats.'"
Although the exact significance of VEB in the presence
of ischaemic heart disease remains enigmatic and a
definition of life-threatening arrhythmias still lacks pre-
cision, drugs having an effect on rhythm must be treated
with suspicion until more information becomes available.
Oxprenolol, a potent beta-receptor blocking agent, does
not appear to have deleterious rhythm properties.
I should like to thank Ciba-Geigy, South Africa, for
supplying the oxprenolol and placebo.
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